Samaritan Moves Development of Caprospinol Ahead Through Advinus Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to run extensive preclinical studies evaluating the Alzheimer’s candidate, then enter Phase I trials by the end of the year.